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Abstract
Asparaginase is fundamental to the treatment of haematological malignancies. 
However, little has been studied on the effects that asparaginase could exert on 
solid tumours. Thus, this study aimed to evaluate the effects of asparaginase on an 
oral carcinoma cell line. The cytotoxicity of asparaginase in SCC-9 (tongue squamous 
cell carcinoma) and HaCaT (human keratinocyte) cell lines was evaluated with MTT 
cell viability assay. The cells were treated with asparaginase at 0.04, 0.16, 0.63, 1.0, 
1.5, 2.5, and 5.0 IU/mL. Dose-response curves and IC50 values were obtained and 
the Tumour Selectivity Index (TSI) was calculated. The effect of asparaginase on 
procaspase-3 and nuclear factor κB (NFκB) expression was evaluated with western 
blot because it was reported that the overexpression of NFκB has been shown to 
contribute to tumour cell survival, proliferation, and migration. Caspase 3/7 stain-
ing was performed to identify cell death using flow cytometry. Effective asparagi-
nase concentrations were lower for SCC-9 cells when compared to HaCaT cells. The 
cytotoxicity results at 48 and 72 hours were significantly different for SCC-9 cells. 
The TSI indicated that asparaginase was selective for the tumour cells. A decrease 
in procaspase-3 and NFκB protein levels was observed in SCC-9 cells. Furthermore, 
asparaginase resulted in significant apoptosis after 48 and 72 hours. Based on these 
results, asparaginase was cytotoxic in a dose- and time-dependent manner, induces 
apoptosis, and reduces NFκB expression in oral cancer cells. These results encourage 
further studies on the effectiveness of this enzyme as a treatment for solid tumours, 
especially head and neck cancer.
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1  | INTRODUC TION
Asparaginase is an enzyme that is commercially employed by the 
food industry to decrease the concentration of acrylamide, a po-
tentially carcinogenic substance 1 that results from the reaction 
between the asparagine amino acid and reducing sugars during the 
thermal processing of food.2
Asparaginase is also used as coadjuvant in the treatment of 
haematological malignancies such as acute lymphoblastic leukemia 
(ALL), therefore it is included in the list of essential medicines of 
the World Health Organization.3 Even though it is primarily used 
to treat ALL,4 clinical trials have been conducted to evaluate its 
effects on tumours of the lymphatic and hematopoietic system, 
such as lymphoblastic lymphoma5 and extranodal lymphoma of 
NK/ T cells.6
Yet, studies focusing on the effect of asparaginase on solid tu-
mours are scarce. The in vitro studies on the antitumor activity of as-
paraginase against breast,7-11 ovarian 10-14 and hepatocellular cancer 
10,15,16 cell lines, among others, are reported in Table 1. Furthermore, 
one clinical trial demonstrated that polyethylene glycol-conjugated 
L-asparaginase is generally well tolerated in patients with advanced 
solid tumours, and that a dosage of 2000 IU/m2 by intramuscular in-
jection every 2 weeks resulted in a significant depletion of serum 
L-asparagine.11
The enzyme acts by reducing plasma levels of asparagine 
amino acid, catalyzing the conversion of asparagine to aspartic 
acid.17 Unlike normal cells, tumour cells are unable to guarantee 
their supply of asparagine, which makes them dependent on ex-
tracellular asparagine.17 Thus, when asparaginase is administered, 
asparagine is depleted, which leads to cell cycle arrest and cell 
death.17
Although the exact mechanism by which asparaginase exerts 
its anticancer effects is not fully understood,18 distinct processes 
have been proposed. A recent in vitro study on laryngeal carcinoma 
cells found that treatment with asparaginase leads to an increase in 
cleaved caspase-3, which in turn resulted in cell death by apoptosis 
in a dose- and time-dependent manner.19 Even though the overex-
pression of nuclear factor κB (NFκB) has been shown to contribute 
to tumour cell survival, proliferation, and migration,20 the effect of 
asparaginase on NFκB in head and neck carcinoma cell lines has not 
yet been reported.
Treatment of head and neck squamous cell carcinoma (HNSCC) 
involves a combination of surgery, radiotherapy, and chemother-
apy, depending on the stage of cancer.1 Despite the different forms 
of treatment, the mortality rate is considered high with an overall 
5-year survival rate of approximately 50% to 60%.21 Therefore, it 
is necessary to develop new therapies that are more effective and 
less invasive.22
In a literature search (Table 1), no studies were found reporting 
on the effects of asparaginase on oral carcinoma. Therefore, this 
study aimed to investigate the antineoplastic effects of asparaginase 
on an oral carcinoma cell line.
2  | RESULTS
2.1 | Asparaginase reduces oral cancer cell viability 
in a dose- and time-dependent manner
The dose-response curves, established for both the SCC-9 and HaCaT 
cell lines after treatment with asparaginase for 48 or 72 hours, are 
shown in Figure 1. At concentrations higher than 1 IU/mL, the cell viabil-
ity tended to stabilize and form a plateau with SCC-9 cells (Figure 1A,B). 
This was not the case with the keratinocyte cell line (HaCaT), in which 
the viability decreased proportionally to the dose of asparaginase 
(Figure 1C,D). Additionally, it is important to note that, with SCC-9 cells, 
the difference in viability between cells treated with the vehicle and 
those treated with asparaginase was statistically significant at concen-
trations equal to or greater than 1 IU/mL after 48 hours and 0.64 IU/
mL after 72 hours of treatment (Figure 1E,F). With HaCaT cells, this dif-
ference was only significant at concentrations equal to or greater than 
1.5 IU/mL after 48 hours and 1 IU/mL after 72 hours (Figure 1G,H). 
These results suggest that asparaginase was more effective against the 
HNSCC cell line (SCC-9) than the keratinocyte cell line (HaCaT).
The median cell viability after treatment of both cell lines with 
different concentrations of asparaginase for 48 or 72 hours is pre-
sented in Table 2. There was a statistically significant difference be-
tween the 48 and 72 hours results for all concentrations with SCC-9 
cells, while for HaCaT cells this difference was significant only for 
0.64 and 1 IU/mL. In view of these results, it is considered that as-
paraginase affects SCC-9 cells in a time-dependent manner.
The dose-response curve results also enabled the calculation of 
IC50 values (Figure 1A-D), which were 4.7 and 0.6 IU/mL for SCC-9 at 
48 and 72 hours, respectively. For HaCaT cells, the IC50 values were 
6.6 and 7.8 IU/mL for 48 and 72 hours, respectively.
2.2 | TSI indicates that asparaginase is selective 
for oral cancer cells
The TSI was calculated for each experimental treatment period, 
according to the formula previously described. The TSI for 48 and 
72 hours were respectively 1.4 and 13. Considering that a TSI higher 
than 1 indicates that the treatment is selective for the tumour cell 
line, asparaginase is markedly selective for the SCC-9 cell line, espe-
cially after a 72-hour treatment.
2.3 | Asparaginase reduces expression of 
Procaspase-3 and NFκB in oral cancer cells
A western blot assay to evaluate protein expression in SCC-9 cells 
treated with asparaginase at IC50 showed reduced procaspase-3 
after 48 and 72 hours (Figure 2 and Figure S1). The blot quantifica-
tion indicates that asparaginase treatment causes reduction of the 
procaspase-3 levels to a median of 50.4% in 48 hours and 41.6% in 
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TA B L E  1   Summary of descriptive characteristics of the studies that assessed the effects of asparaginase on solid tumours
 
Study 




In vitro LnCap (human prostate carcinoma), 
MCF7 (human breast carcinoma), 
SKOV-3, CaOV (human ovarian 
carcinoma), HepG2 (human 
hepatocellular carcinoma), HT-1080 
(human fibrosarcoma, GGNC-1 (rat 
Gasser's ganglion neurinoma cells), 
and EPNT-5 (murine glioblastoma) 
cell lines
L-asparaginase (derived from 
Erwinia carotovora - ECAR 
LANS); L-asparaginase (from 
Escherichia coli - Medac) 
- 0.2-10 IU/mL
L-asparaginases resulted in a significant 
dose-dependent decrease in viable 
cells. SKOV-3, HepG2, GGNC-1 
and EPNT-5 exhibited the highest 
sensitivity to the cytostatic effect of 
L-asparaginases. Medac asparaginase 
was effective in increasing the 
number of LnCap apoptotic cells. 
L-asparaginase combined with 
doxorubicin (0.5 µg/mL) increased the 
number of MCF7 apoptotic cell. 
Ji et al 
(2017)19
In vitro Tu212 and Tu686 (human laryngeal 
squamous cell carcinoma) cell lines
Asparaginase (from E 
chrysanthemi) - 0-2 IU/mL
Asparaginase induced remarkable 
cytotoxicity, autophagy and caspase-
dependent apoptosis in Tu212 and 
Tu686 cells. Autophagy was mediated 
by inactivation of Akt/mTOR and 
activation of the Erk signaling 
pathway.
Kim et al 
(2015)12
In vitro and 
in vivo
In vitro: MC38 (murine colon 
adenocarcinoma), 4T1 (murine 
mammary carcinoma) and AsPC1 
(human pancreas carcinoma) cell lines; 
In vivo: mice with tumours induced by 
inoculation of MC38, 4T1 or AsPC1 
cells
L-asparaginase secreted 
(0.2 mg/mL culture 
supernatant) or delivered to 
tumour tissue by Salmonella 
typhimurium engineered to 
express the enzyme; Leunase 
- 5 IU/mL
In vitro cytotoxicity induced by both S 
typhimurium-derived L-asparaginase 
(L-asparaginase-containing bacterial 
culture supernatant) and Leunase 
(asparaginase used clinically). In 
vivo tumour size regression induced 
by L-asparaginase expressed and 
released by S typhimurium within the 
tumour tissue.
Knott et al 
(2018)14
In vivo In vivo: mice with tumours induced by 
inoculation of 4T1 (murine mammary 
carcinoma) or MDA-MB-231 (human 
breast carcinoma) cells
In vivo: 200 µL of 60 U 
L-asparaginase five times a 
week intraperitoneally
Treatment with L-asparaginase reduced 
serum asparagine to undetectable 
levels, not significantly altering 
primary tumours, but reducing 
metastasis. When asparagine 
synthetase-silenced cells were 
injected into mice treated with 
L-asparaginase, metastases were 
nearly undetectable, and a reduction 




In vitro T47D, BT20, MCF-7 (human breast 
carcinoma), Walker 256 (rat breast 
carcinoma) and HeLa (human cervical 
carcinoma) cell lines
L-asparaginase (from 
Tetrahymena pyriformis or E 
coli) - 0.01 IU
Asparaginase derived from both 
T pyriformis and E coli resulted in 
antiproliferative activity on the breast 
cancer cell lines (T47D, BT20 MCF-7 
and Walker 256). No difference 
was observed in HeLa cells when 
compared to control.
Lorenzi et al 
(2006)8
In vitro OVCAR-3, OVCAR-4, OVCAR-5, 
OVCAR-8, IGROV1, and SKOV-3 
(human ovarian cancer) cell lines
L-asparaginase (from E coli) 
serially diluted for a dose-
response curve
Asparagine synthetase silencing 
enhanced the cytotoxic effects 
of L-asparaginase, which suggests 
asparaginase synthetase as a 
biomarker for selection of patients 
who shall undergo treatment with 
L-asparaginase.
Lorenzi et al 
(2008)7
In vitro A total of 19 ovarian cancer cell lines L-asparaginase (from E coli) 
serially diluted for a dose-
response curve
The expression of asparagine 
synthetase, measured by 
immunoassay, is a strong predictor 
of L-asparaginase activity in ovarian 
cancer cell lines.
(Continues)
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Panosyan et 
al (2014)33
In vitro and 
in vivo
In vitro: DAOY, GBM-ES, U87 (human 
brain tumour) and GL-261 (murine 
glioma) cell lines; In vivo: mice with 
tumours induced by inoculation of 
DAOY cells
Asparaginase (from E coli)
In vitro: 0.0625-2 IU/mL
In vivo: 2 IU/g of body weight
Asparaginase in vitro resulted in 
dose-dependent and variable 
growth inhibition and in reduction of 
neurosphere formation. Co-treatment 
with gemcitabine or etoposide 
resulted significantly better. In vivo 
results showed sustained deamination 
of asparagine after treatment with 
asparaginase. Asparaginase combined 
with temozolomide resulted in 
significant growth suppression.
Tardito et al 
(2007)34
In vitro HT1080 (human fibrosarcoma), RD 
(human rhabdomyosarcoma), SW872 
(human liposarcoma), HOS, SAOS-2, 
and U2OS (human osteosarcomas) 
cell lines
Asparaginase (from E 
chrisanthemy) - 0.001-10 IU/
mL
Asparaginase produced a marked 
decrease of cell viability and 
significant activation of Caspase-3 
in HT1080 and SW872 cells. In 
contrast, RD, SAOS-2, HOS, and 
U2OS cells exhibited only a partial 
growth suppression. Flow cytometry 
indicated apoptosis in all cells (except 
for RD) treated with asparaginase, 
and its association to a glutamine 
synthetase inhibitor (MSO) increased 
even further the number of apoptotic 
cells.
Tardito et al 
(2011)15
In vitro HepG2, Hep3B, Huh-7, PLC-PRF-5, 
and Huh-6 (human hepatocellular 
carcinoma) cell lines
Asparaginase (from E 
chrisanthemy) – 1 IU/mL
Asparaginase increased glutamine 
synthetase expression and activity. 
Only HepG2 cells were sensitive 
to asparaginase alone, while its 
association to a glutamine synthetase 
inhibitor resulted in significantly 
decreased viability. Asparaginase 
caused apoptosis and increased 
caspase-3 in HepG2 cells and 
combined with MSO induced G2/M 
cell cycle arrest.
Taylor et al 
(2001)11




In vitro: human tumour clonogenic 
assay with fresh breast, colon, lung 
and ovary tumours, melanoma, and 
non-Hodgkin's lymphoma samples
Clinical trial: malignant melanoma (11), 
non-small cell lung cancer (6), sarcoma 
(2), colon cancer (2), bladder cancer 
(1), Cholangio-carcinoma (1), Multiple 
myeloma (1), Renal cell carcinoma (1), 
Salivary gland tumour (1), Small cell 
lung cancer (1)
In vitro: polyethylene 
glycol-conjugated (PEG) 
L-asparaginase −0.075 and 
0.75 IU/mL
Clinical trial: PEG-L-
asparaginase administered by 
intramuscular injection every 
2 weeks - 250-2000 IU/m2
Malignant melanoma was the most 
sensitive tumour type to PEG-L-
asparaginase, especially at the highest 
concentration. PEG-L-asparaginase at 
a dosage of 2000 U/m2 every 2 weeks 
results in consistent depletion of 
serum L-asparagine. Treatment with 
PEG-L-asparaginase was generally 
well tolerated, with grade 1 and grade 
2 fatigue/weakness, nausea/vomiting, 
and anorexia/weight loss occurring 
more consistently at 2,000 IU/
m2. Further studies are needed to 
determine the antitumor activity 
of PEG-L-asparaginase in patients 
with solid tumours, especially those 
with malignant melanoma, since 
this tumour demonstrated in vitro 
sensitivity.
TA B L E  1   (Continued)
(Continues)
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72 hours when compared to the vehicle-treated cells. The decrease 
in procaspase-3 levels indicated that it was cleaved into caspase-3, 
which is its active form. Given that this protein is responsible for the 
induction of apoptosis, these results suggest that asparaginase may 
induce apoptosis in SCC-9 cells, which was then confirmed by flow 
cytometry assay.
As shown in Figure 3, treatment with asparaginase at IC50 for 
48 hours reduced the expression of the NFκB transcriptional factor 
in SCC-9 cells (Figure S2). The blot quantification suggests that as-
paraginase caused the reduction of NFκB (to 47.1%) when compared 
to vehicle-treated cells.
2.4 | Asparaginase induces apoptosis in oral 
cancer cells
Aligned with the findings from western blotting, we also showed 
that asparaginase induced apoptosis in SCC-9 through increased lev-
els of Caspase3/7 under 48 and 72 hours treatment with asparagi-
nase (Figure 4A,B, ***P < .0001). Therefore, the apoptotic effect of 
asparaginase upon oral cancer cells is clear.
3  | DISCUSSION
To our knowledge, this is the first study to report on the effects of 
asparaginase on the oral cancer cell line. In fact, only a few stud-
ies have been published on the potential of the enzyme on solid 
tumours. Ji et al 19 described a significant reduction in the cell vi-
ability of Tu212 and Tu686 laryngeal squamous cell carcinoma cell 
lines treated for 48 hours with asparaginase at concentrations rang-
ing from 0.063 to 2 IU/mL, with 2 IU/mL resulting in less than 50% 
viability in both cell lines. Tardito et al 15 proposed that a much lower 
dose of asparaginase is effective against the HepG2 hepatocellular 
carcinoma cell line, with an IC50 value of 0.1 IU/mL after a 48-hour 
treatment. Our results indicate that a higher concentration of as-
paraginase is necessary for the induction of comparable effects in 
SCC-9 (IC50 4.7 IU/mL, 48 hours). However, a comparable IC50 value 
was obtained for the SCC-9 cell line after 72 hours (0.6 IU/mL). This 
difference between the IC50 values after 48 and 72 hours, along with 
the analyses of cell viability displayed in Table 2, highlights the im-
portance of time on the treatment of SCC-9 cells with asparaginase. 
Therefore, it is reasonable to hypothesize that the prolonged activ-
ity of asparaginase on SCC-9 cells results in continuous asparagine 
depletion, which reduces protein synthesis and ultimately inhibits 
proliferation, induces apoptosis 12,23,24 and reflects on cell viability.4
The IC50 values for the HaCaT cells after both 48- and 72-hour 
treatment (6.6 and 7.8 IU/mL, respectively) were higher than 5 IU/
mL, the highest concentration used in the dose-response curve. As 
seen in Figure 1, no tested concentration of asparaginase could re-
duce cell viability to less than 40% in the keratinocyte cell line, there-
fore these IC50 values are approximated, calculated by the non-linear 
regression model. In contrast, the IC50 measures for the SCC-9 cell 
line are within the concentration range used in the dose-response 
curve. These observations demonstrate that asparaginase was less 
effective against HaCaT cells in comparison to SCC-9 cells.
 
Study 
design Cell type/Tumour Asparaginase Main results
Yu et al 
(2012)9
In vitro HEYA-8, CAOV-3, SKOV-3, and 
OVCAR-8 (human ovarian cancer) 
cell lines
L-asparaginase - 0.3-3 IU/mL L-asparaginase significantly decreased 
invasiveness and adhesion of ovarian 
cancer cells, as did reduce quantity 
and organization of actin stress 
fibers. L-asparaginase also activated 
autophagy pathways.
Zhang et al 
(2013)16
In vitro and 
in vivo
In vitro: MHCCLM3, MHCC97H, 
SMMCCLM3, and PLC (hepatocellular 
carcinoma) cell lines; In vivo: mice 
with tumours induced by inoculation 
of MHCCLM3 cells
L-asparaginase
In vitro: 0.5 and 1 µ/mL
In vivo: 20 µ/g administered 
intraperitoneally every other 
day
Cells with low asparagine synthetase 
expression were more sensitive to 
L-asparaginase then cells with high 
expression. Asparagine synthetase-
knockdown cells, both in vitro and 
in vivo (in xenograft tumours), 
had respective proliferation and 
tumour size significantly decreased 
and reduced after treatment with 
L-asparaginase.
Zhang et al 
(2016)25
In vitro A549 and H1975 (human pulmonary 
carcinoma) cell lines
Asparaginase (derived from 
Erwinia) - 0.0625-2 IU/mL
Asparaginase induced remarkable 
cytotoxicity in a dose-dependent 
manner, apoptosis and autophagy in 
lung adenocarcinoma cells. By treating 
cancer cells with asparaginase and 
inhibiting autophagy, cytotoxicity was 
increased, as well as the activity of 
caspase 3.
TA B L E  1   (Continued)
862  |     BORGES Et al.
Additionally, asparaginase was considered selective for the tu-
mour cells, with a TSI of 1.4 for 48 hours and 13 for 72 hours. The 
especially high TSI after a 72-hour treatment might be due to the 
time-dependent effect as previously described. Considering the 
low or absent expression of asparagine synthetase in most cancers, 
there is a higher demand for asparagine and glutamine.17 Yet, we 
know that asparaginase reduces the bioavailability of both amino 
acids thereby oral cancer cells ought to be more susceptible to as-
paraginase than the keratinocyte cells.23,24
A decrease in procaspase-3 was observed upon asparaginase 
treatment for both 48 and 72 hours in a time-dependent manner 
(Figure 2). Ji et al 19 report a dose and time-dependent increase in 
the number of annexin-V marked cells that suggest apoptosis, and 
in the levels of cleaved caspase-3 and poly ADP-Ribose polymerase 
(PARP), both proapoptotic proteins, after a 24- or 48-hour treatment 
of Tu212 and Tu686 laryngeal squamous cell carcinoma cells with 
asparaginase. Zhang et al 25 also identified asparaginase as an induc-
tor of apoptosis in A549 and H1975 pulmonary adenoma cell lines, 
F I G U R E  1   Dose-response curves, 
IC50 values and cell viability for each cell 
line treated with asparaginase for 48 and 
72 h in different concentrations. A–D, 
Dose-response curves (normalized cell 
viability vs asparaginase concentration 
in the log) and non-linear regression (red 
line). A plateau formed when SCC-9 cells 
were treated with higher concentrations 
of asparaginase (A and B), which was 
not observed with HaCaT cells (C and 
D). Under the experimental conditions 
described in this study, asparaginase was 
not able to reduce cell viability by 50% or 
more. Representation of medians ± range. 
E–H, Cell viability results. Difference 
between cell viability in vehicle-treated 
cells (0 IU/mL) and cells treated with 
asparaginase becomes significant at lower 
concentrations with SCC-9 cells (E and 
F) in comparison to HaCaT cells (G and 
H). Representation of medians ± range. 
Kruskal-Wallis test and Dunn's post test 
were used to compare all groups (different 
concentrations) in the same experimental 
condition. *P < .05
SCC-9 - 48h
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describing a significant increase in annexin-V-marked cells after 
24 hours of treatment. The reduced bioavailability of asparagine and 
glutamine is associated with apoptosis once that the cells are unable 
to properly synthesize proteins due to cell death.12,23,24
In our study, NFκB was decreased in SCC-9 cells treated with as-
paraginase. The NFκB family, also called p65, is comprised of five tran-
scription factors that form distinct protein complexes that bind to DNA 
sequences in the promoter regions of responsive genes. It regulates 
cellular processes that relate to immune and inflammatory responses 
and cancer progression.26,27 NFκB not only promotes tumour cell pro-
liferation, suppresses apoptosis, and induces angiogenesis, but also 
induces epithelial–mesenchymal transition, which facilitates distant 
metastasis.28 It was demonstrated that turmeric inhibited NFκB activa-
tion and down-regulated the products of NFκB-controlled genes linked 
to cancer survival (Bcl-2, cFLIP, XIAP, and cIAP1), proliferation (cyclin 
D1 and c-Myc), and metastasis (CXCR4).28 Squarize et al 29 showed that 
in HNSCC cells (HN12, HN13, HN30) the activity of interleukin-6 (IL-6) 
is increased and depended on NFκB. NFκB inhibition resulted in the 
downregulation of the IL-6 promoter and inhibition of the signal trans-
ducer and activator of transcription-3 (STAT3) activity in HNSCC cells.29 
STAT3 promotes tumour progression by regulating the expression 
of the cell cycle, survival, and pro-inflammatory genes, in addition to 
controlling mitochondrial function, metabolism, and stemness.30 Also, 
NFκB downregulation in SCC-9 cells results in growth inhibition, in-
creased apoptosis, and reduced cell migration and invasion.31 The inhi-
bition growth caused by NFκB decreased activity was found in another 
HNSCC cell line (CAL-27) treated with curcumin.32 Thus, asparaginase 
treatment could be linked to caspase-3 activation or the regulation of 
proliferation mechanisms mediated by reduced NFκB levels.
Based on these results, we concluded that asparaginase is cyto-
toxic to the oral cancer cell line in a dose- and time-dependent man-
ner; and it induces apoptosis, which was confirmed by flow cytometry 
assays. Moreover, asparaginase down-regulates NFκB, an important 
molecule that modulates cell growth and migration. Altogether, these 
results encourage further studies on the effectiveness of this enzyme 
as a treatment for solid tumours, including head and neck cancer.
4  | MATERIAL AND METHODS
4.1 | Asparaginase
The lyophilized asparaginase enzyme, derived from Escherichia coli, 
was purchased from Sigma-Aldrich (A3809; City?, Country?). 100 IU 
of asparaginase was diluted in 1 mL deionized water and kept at 
−20ºC until used.
4.2 | Cell lines and culture conditions
A tongue squamous cell carcinoma cell line (SCC-9) and a human 
keratinocyte cell line (HaCaT) were used for the experiments. They 
were purchased from ATCC (Manassas, VA, USA), and consider-
ing that all experiments were conducted on commercially available 
Concentration IU/mL
Median cell viability (±Range) (%)
P-value48 h 72 h
SCC-9
0.04 99 (±93.9-110.8) 86.1 (±77.1-97.4) *
0.16 82.5 (±76.8-94.8) 67.1 (±51.7-80.3) ***
0.64 63.5 (±51.9-77.3) 40.3 (±35.5-58.1) ***
1 55.5 (±49.7-64.4) 37 (±33-45.2) ***
1.5 56.1 (±48.6-64.35) 37 (±31.9-45.4) ***
2.5 59 (±44.1-74.3) 34.2 (±30.6-43.7) ***
5 53.5 (±42.7-71.74) 34.2 (±31.5-42.6) ***
HaCaT
0.04 95.7 (±88-98.3) 92.1 (±76.4-99.4) .5972
0.16 95.6 (±85.8-99.3) 88.6 (±68.5-98) .0706
0.64 86 (±75.9-97) 73.8 (±62-87.3) **
1 75.7 (±65.1-97.1) 69.2 (±54.5-81.5) *
1.5 69.6 (±61.3-77) 63.8 (±51.3-76) .0656
2.5 64.1 (±57-82.8) 62.2 (±53.2-68.4) .2486
5 60.7 (±30.5-69.1) 56.9 (±49.5-67.8) .9316
Note: Note Mann-Whitney test was used to compare 48 and 72 h results.
*P ≤ .05. 
**P ≤ .005. 
***P ≤ .0002. 
TA B L E  2   Median cell viability after 
treatment of SCC-9 and HaCaT with 
asparaginase in different concentrations 
and in different treatment periods
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cell lines, our study was not submitted to an ethics committee. 
The SCC-9 cell line was cultured in 1:1 Dulbecco's Modified Eagle 
Medium (DMEM)/F12 with 10% foetal bovine serum and 1% anti-
biotics (penicillin-streptomycin). The HaCaT cell line was cultured in 
DMEM supplemented with 10% foetal bovine serum and 1% anti-
biotics. The cells were incubated in 5% CO2 at 37°C. Cell culture 
reagents were purchased from Sigma-Aldrich.
4.3 | Cell viability assay – dose-response curve
The SCC-9 and HaCaT cells were seeded into 96-well plates at a den-
sity of 5 × 103 cells/well and incubated overnight. Cells were treated 
with 0.04, 0.16, 0.64, 1.0, 1.5, 2.5 or 5.0 IU/mL asparaginase for 48 
and 72 hours. Deionized water was used as a vehicle. After the treat-
ment, 10 μL of MTT solution (3,[4,5-dimethylthiazol-2yl]-2,5-diphe-
nyltetrazolium bromide) (Sigma-Aldrich) at 5 mg/mL was added to 
each well, followed by incubation for 4 hours at 37°C. The medium 
was then aspirated and 100 μL of acidified isopropanol was added 
to dissolve formazan crystals. Absorbance was measured at 570 nm 
in a DTX 800 reader (Beckman Coulter, City?, Country?). The assays 
were performed in triplicate.
The concentration capable of inducing 50% cell cytotoxicity (IC50) 
in each cell line was estimated from the cell viability assay results 
through a non-linear regression, and the Tumour Selectivity Index 




. A TSI higher than 1 suggests that aspara-
ginase is selective to the tumour cell line (SCC-9), in comparison to 
the control cell line (HaCaT).
4.4 | Western blot analysis
The SCC-9 cells were treated with asparaginase at the IC50 concen-
tration for 48 or 72 hours, with deionized water as a vehicle. They 
were then washed, lysed in a buffer and centrifuged. The protein 
fraction was collected and quantified by the Lowry method. Samples 
(30 µg denatured proteins in 30µL buffer) were loaded in a 10% 
acrylamide gel and electrophoresed at 100V. The proteins were 
then transferred to a PVDF membrane, which was blocked with 
a 5% blocking solution (milk albumin) for one hour and incubated 
overnight with the Caspase-3 (SC7148), NFκB p65 (D14E12) (Cell 
Signaling Technology, Davners, MA, USA) or GAPDH (SC47724) 
(Santa Cruz Biotechnology, City?, Country?) primary antibodies at 
4ºC. After incubation, the membrane was washed and incubated with 
the secondary antibody (Abcam, City?, Country?) for 1 hour at 4ºC. 
After washing again, the membrane was covered with ECLPRIME 
(GE Health Care, Little Chalfont, UK) and images were acquired with 
a chemiluminescence imager (Amersham Imager 600; GE Health 
Care). Image J software (National Institute of Health, Bethesda, MD, 
F I G U R E  2   Expression of procaspase-3. A, Treatment with 
asparaginase at IC50 reduced procaspase-3, which suggests its 
cleavage into caspase-3 and is indicative of apoptosis. B, Relative 
quantification of the grey means values of the western blots for 48 































































F I G U R E  3   Expression of nuclear factor (NF) κB. A, Treatment 
with asparaginase at IC50 for 48 h reduced the levels of NFκB. B, 
Relative quantification of the grey means values of the western 
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USA) was used to measure the grey mean value (GMV) of each blot 
and its surrounding region (background). The measurements were 
inverted and the background was deducted from the blots GMVs. 
The protein bands were relatively quantified as a ratio of the net 
procaspase-3 or NFκB value over its relative net GAPDH value.
4.5 | Apoptosis assay
In order to confirm the results from the western blot, flow cytom-
etry was used to analyze cell death events. SCC-9 cells were treated 
with asparaginase at the IC50 concentration for 48 or 72 hours, with 
deionized water as a vehicle. The CellEvent Caspase-3/7 Green 
Flow Cytometry Assay Kit (Life Technologies, City?, Country?) was 
used according to the kit's instructions. Briefly, 1 µL of CellEvent 
Caspase-3/7 Green Detection Reagent was added to samples con-
taining 1 mL of cell suspension at 1 × 105 cells/mL and incubated for 
25 minutes at 37°C. Then, 1 µL of 1 mmol/L SYTOX AADvanced 
dead cell stain solution was added to samples and incubated for 
5 minutes at 37°C. The analysis of the samples was performed on 
the BD Accuri C6 Plus flow cytometer (BD Life Sciences, City?, 
Country?). A minimum of eight readings were performed.
4.6 | Statistical analyses
The statistical analysis for the cell viability assay was performed on 
the results from nine wells at each concentration. The Kruskal-Wallis 
test and Dunn's post test were applied to compare the results of 
multiple groups (different concentrations) for each cell line in each 
different treatment period. To assess time-dependency the Mann-
Whitney test was used to compare the results of each concentra-
tion at 48 and 72 hours. The IC50 values were calculated through 
a non-linear regression model. The Student's T-test was applied to 
the flow cytometry data. All statistical tests were performed with 
the GraphPad 5.0 program for Windows (GraphPad, San Diego, CA, 
USA). The significance level was P < .05.
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